Search
Naldemedine
go.drugbank.com/drugs/DB11691ApprovedInvestigationalNaldemedine is an opioid receptor antagonist [FDA Label]. … Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation.
Categories: Peripheral Opioid Receptor AntagonistsPanitumumab
go.drugbank.com/drugs/DB01269ApprovedInvestigationalPanitumumab (ABX-EGF) is a recombinant human IgG2 monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). This drug is an antineoplastic agent.
Categories: Epidermal Growth Factor Receptor Antagonist, EGFR (Epidermal Growth Factor Receptor) inhibitorsCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalthe convenience of daily or twice-daily dosing. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Products: NOVOSEF 1 G/10 ML IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET, NOVOSEF 1 G/3,5 ML IM ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADETAlosetron
go.drugbank.com/drugs/DB00969ApprovedWithdrawnIn June 2002, the FDA approved a supplemental new drug application allowing the remarketing of the drug under restricted conditions of use. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured
Categories: Serotonin Receptor Antagonists, Serotonin 3 Receptor AntagonistsFormestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnFormestane was the first selective, type I, steroidal aromatase inhibitor used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. … Currently, formestane (categorized as an anti-estrogenic agent) is prohibited from use in sports in accordance to the regulations of the World Anti-Doping Agency.
Misoprostol
go.drugbank.com/drugs/DB00929ApprovedInvestigational[L7616,L7619,A181589,A181583,A181697] The stimulation of prostaglandin receptors in the stomach reduces gastric acid secretion, while stimulating these receptors in the uterus and cervix can increase the … Misoprostol is a prostaglandin analog used to reduce the risk of NSAID related ulcers, manage miscarriages, prevent post partum hemorrhage, and also for first trimester abortions.
Categories: Prostaglandins E, SyntheticMacitentan
go.drugbank.com/drugs/DB08932ApprovedInvestigationalMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. … A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.
Categories: Endothelin Receptor Antagonists, Endothelin A Receptor AntagonistsDimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigationaleffects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade. … [L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory
Ocrelizumab
go.drugbank.com/drugs/DB11988ApprovedInvestigational[A31739] Compared to non-humanized CD20 antibodies such as [rituximab], ocrelizumab is expected to be less immunogenic with repeated infusions, improving the benefit-to-risk profile for patients with MS … It was later approved by Health Canada in August 2017, making the drug the first available treatment for PPMS in both the US and Canada.
Exemestane
go.drugbank.com/drugs/DB00990ApprovedInvestigationalIt irreversibly binds to the active site of the enzyme resulting in permanent inhibition. … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal